

Valeria Leuci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8900998/publications.pdf>

Version: 2024-02-01

23
papers

604
citations

623188

14
h-index

676716

22
g-index

23
all docs

23
docs citations

23
times ranked

810
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opinion on Biological Therapy, 2012, 12, 673-684.	1.4	124
2	Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features. Clinical Cancer Research, 2013, 19, 4347-4358.	3.2	81
3	Cytokine-Induced Killer Cells Eradicate Bone and Soft-Tissue Sarcomas. Cancer Research, 2014, 74, 119-129.	0.4	67
4	CD44v6 as innovative sarcoma target for CAR-redirectioned CIK cells. Oncoimmunology, 2018, 7, e1423167.	2.1	38
5	Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells. Clinical Cancer Research, 2017, 23, 2277-2288.	3.2	34
6	CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 2839.	1.8	34
7	BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody. Clinical Cancer Research, 2018, 24, 3377-3385.	3.2	31
8	CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. Clinical Cancer Research, 2020, 26, 6321-6334.	3.2	24
9	Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers. Journal of Immunotherapy, 2012, 35, 579-586.	1.2	21
10	Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.. Oncoimmunology, 2018, 7, e1465161.	2.1	20
11	Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors. Current Gene Therapy, 2014, 14, 52-62.	0.9	20
12	Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. Expert Opinion on Biological Therapy, 2014, 14, 1259-1270.	1.4	18
13	Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. Journal of Translational Medicine, 2016, 14, 119.	1.8	18
14	Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34+ cells and T lymphocytes: Implications for the use of low viral doses and large-size vectors. Journal of Biotechnology, 2011, 156, 218-226.	1.9	14
15	Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective. Cells, 2021, 10, 543.	1.8	14
16	Efficient Transcriptional Targeting of Human Hematopoietic Stem Cells and Blood Cell Lineages by Lentiviral Vectors Containing the Regulatory Element of the Wiskott-Aldrich Syndrome Gene. Stem Cells, 2009, 27, 2815-2823.	1.4	11
17	Adoptive immunotherapy against sarcomas. Expert Opinion on Biological Therapy, 2015, 15, 517-528.	1.4	11
18	Sustained Long-Term Engraftment and Transgene Expression of Peripheral Blood CD34+Cells Transduced with Third-Generation Lentiviral Vectors. Stem Cells, 2008, 26, 1620-1627.	1.4	8

#	ARTICLE	IF	CITATIONS
19	EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma. <i>Cells</i> , 2021, 10, 2893.	1.8	7
20	Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 211-222.	0.9	4
21	Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 655-666.	1.4	3
22	Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells. <i>Journal of Translational Medicine</i> , 2015, 13, O1.	1.8	2
23	PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas – A Preclinical and Translational Study. <i>Cancers</i> , 2021, 13, 6295.	1.7	0